Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
about
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic miceMKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6Inhibition of excessive mitochondrial fission reduced aberrant autophagy and neuronal damage caused by LRRK2 G2019S mutationBiochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimersRac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2)LRRK2 and the stress response: interaction with MKKs and JNK-interacting proteinsLRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site statusSynaptic vesicle trafficking and Parkinson's diseaseLRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutationsInsight into the mode of action of the LRRK2 Y1699C pathogenic mutantLRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative studyPhosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylationThe Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sitesMembrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylationIdentification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycleDysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegansLRRK2 phosphorylates novel tau epitopes and promotes tauopathyG2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarizationInhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's diseaseHeterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implicationsIs inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasisRoco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutationsParkinson's disease and immune system: is the culprit LRRKing in the periphery?Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvationInhibition of LRRK2 kinase activity stimulates macroautophagyLeucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brainEnhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019SDiapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.Abnormal visual gain control in a Parkinson's disease model.Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegenerationPathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue.The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylationERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.Mitochondrial dysfunction driven by the LRRK2-mediated pathway is associated with loss of Purkinje cells and motor coordination deficits in diabetic rat model.The R1441C mutation alters the folding properties of the ROC domain of LRRK2.LRRK2 levels in immune cells are increased in Parkinson's disease
P2860
Q21135493-6449859A-B823-4DDB-A16F-DB06D8325116Q24293070-ACF9E419-1AC7-4144-AF23-FAA6FCE0780DQ24294736-D42D35A8-1614-4BDA-9AA1-7F19FF078FD5Q24296778-FBEEEC40-0F28-4F74-B983-07CED138757CQ24297033-C2463B42-6644-441E-A2D8-1509981B8558Q24298093-7CF3EAFB-0431-4B8D-A45C-554D843FDD05Q24298459-5540C385-B5E9-4156-B859-5C2D4C1E808BQ24300440-99189308-2C9C-4615-8518-788B09DD2022Q24300605-6CFC3F8A-994C-4C16-96E9-C909CCD821B2Q24302024-3DAD40B0-F454-449C-ACE1-23201499ABEFQ24306239-5A6019BB-3BA2-48EB-8147-58A3B39EE550Q24306788-CCC4F130-61CC-40A1-A9E3-32E08F6B0E83Q24307455-45C6F4B8-8977-4B2F-A676-8A2BBF67CB89Q24309417-E495E934-2683-4CE9-898F-5F57C146B550Q24310126-640ED19D-740A-433E-BAA9-E96D9B111690Q24313336-86DCD35F-D26F-4962-BB43-EAA9CEA71FDCQ24316270-D4A44E19-E7CB-4624-B150-987B803B854BQ24317158-33A07E57-90D1-482A-A98D-45E765333B99Q24324231-780C4D59-3B46-4B92-BF0F-D77F8739A7C7Q24338188-57E84FB6-BC84-4D4C-A32E-0EB787956BB4Q24339009-24646787-4D93-45E8-9315-CB651B3C451AQ24609725-E4FAED94-89F8-4AEC-B289-D96CD4D25930Q27013695-E3A5B1C3-46B5-4AC3-A782-CA1ADE62678BQ27026262-05FA067F-BE41-4293-A27C-0FD1C83C7D7CQ27315276-0D1A53B6-837B-41FA-9B17-03BC505BC465Q27681111-C9B9F1EB-C064-4141-9EA9-7A1AC5CE3C3BQ27687171-E6BB05EC-3A75-4797-8997-0383652A91A6Q28115231-D107F518-1818-4E4C-A3C8-61497B265791Q28118311-3FBE5221-5E55-470E-93BC-408D539F3017Q28267434-6B036564-43ED-4D75-82AC-C6766AF9C067Q28589899-42FA9B42-7162-48AF-99F2-3F7A9FAE4F25Q30541996-EABA4D41-1F4E-494F-B07A-93182359923DQ30585664-8BD29FE5-3493-41AC-8B17-8FED30F17023Q30653185-969AA229-5D63-4BA7-BC30-B035001BAA7DQ31028020-EB0094CA-E0F0-4596-A6E2-8ECC521AD828Q33525587-3FD9CA92-259B-480B-90A7-BDFE4169142BQ33593798-65D716F4-08E9-4C28-89F5-F8003F7A0A0EQ33720211-E20887D6-2D47-48BE-930F-05FCEB8D9678Q33758163-3056A522-4FFE-414E-8A72-B0B1AD852AD6Q33765746-0537CA13-ADD1-4216-9CD2-BFF77EF78ACF
P2860
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
@en
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
@nl
type
label
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
@en
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
@nl
prefLabel
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
@en
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
@nl
P2860
P921
P356
P1433
P1476
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
@en
P2093
Elisa Greggio
P275
P2860
P304
AN20090007
P356
10.1042/AN20090007
P5008
P577
2009-04-14T00:00:00Z